Peptide Blog · Research Knowledge Hub
Straightforward explainers in plain English — how to handle vials, what researchers mean by “recovery” or “metabolic” signalling, and how to read lab paperwork. Written for curious readers and research / lab use; not personal medical advice.
No articles matched . Try a compound name, a goal, or a how-to — or browse the shop.
Latest dropsNew this week
A research-first breakdown of the body protection compound - the preclinical-only evidence base, the peptide-vs-steroid question, and why recovery and hormonal claims overreach.
New this week Compound Profiles · TesamorelinThe GHRH analogue mechanism, the narrow approved visceral-fat indication, and where general fat-loss and longevity claims go too far.
Safety & Quality COA · HPLC · mass specThe label is the claim; the COA is the evidence. Mass spectrometry for identity, HPLC for purity, batch numbers for traceability - and the red flags that signal marketing over testing.
Sports & Recovery Compound Profiles · TB-500How TB-500 relates to (but differs from) Thymosin Beta-4, what the preclinical literature actually studies, the human-trial gap, and why it is prohibited in tested sport.
New this week Research Spotlight · TirzepatideThe molecule behind Mounjaro and Zepbound, plain. The dual-receptor mechanism, the SURMOUNT and SURPASS trial data, the licensed-drug vs research-compound distinction.
Comparison SURPASS-2 · head-to-headThe only published head-to-head trial (SURPASS-2), the obesity cross-trial picture, the cost reality, and the honest framing for research-grade vs licensed-drug contexts.
Side effects Hair loss · GI · discontinuationDoes tirzepatide cause hair loss? The SURMOUNT data, the telogen-effluvium mechanism, the GI side-effect picture, and the discontinuation rates - plain.
Flagship explainer
Short chains of amino acids that signal the body to repair, regenerate and regulate. Why billionaires and A-list actors have been running them privately since 2010 - and why the rest of the world is finally catching up.
In the press & primary research
The reporting and primary sources these guides reference. New-U is independent and not affiliated with these organisations - links are provided for research reference only and carry no endorsement either way.
Browse by topic
All articles by category88 articles
Six topic clusters covering everything from the Retatrutide trial data to lab how-tos. Use the chips below to jump.
Retatrutide, tirzepatide and semaglutide research, trial data and regulatory status.
The FDA's April 2026 proposal to remove semaglutide, tirzepatide and liraglutide from the 503B bulks list, explained - plus the June 2026 comment deadline.
A research-side guide to retatrutide (LY3437943) - mechanism, Phase 2 weight-reduction data, the TRIUMPH Phase 3 programme, and the GLP-1 RC-R research-compound posture.
A research-side guide to semaglutide - mechanism, half-life, STEP / SUSTAIN trial data, oral vs injectable, and the GLP-1 RC-S research-compound posture.
A research-side guide to tirzepatide (LY3298176) - mechanism, half-life, SURPASS / SURMOUNT trial data, comparison with semaglutide and retatrutide, and the GLP-1 RC-T research compound posture.
Does tirzepatide cause hair loss? The SURMOUNT data, the telogen-effluvium mechanism, GI side effects, plain.
Head-to-head trial data (SURPASS-2), mechanism difference, cost reality, and the honest comparison framing.
Dual GLP-1 / GIP receptor agonist - the molecule behind Mounjaro and Zepbound. Mechanism, trial data, regulatory status, plain.
Five Phase 3 trials, five indications. Endpoints, timelines and what to watch in 2026/27.
Retatrutide is unapproved. Demand has shifted online. The 4 channels, the COA reality, the counterfeit risk.
The largest weight-loss figure in the published pharmacological literature. Numbers, dose-response, honest comparison.
A single molecule hitting GLP-1, GIP and glucagon receptors. The mechanism, the trial data, the regulatory truth.
Retatrutide (LY3437943) is unlicensed in the UK and only available as a research compound. A plain-English guide to MHRA framing, supplier checks, GBP pricing and tracked UK delivery.
Semaglutide is a peptide and a GLP-1 receptor agonist. What GLP-1 is, how the class works, and how research-use peptides differ from approved medicines.
Side-by-side comparison of two leading metabolic peptides - mechanisms, selectivity, and published research.
BPC-157, TB-500 and the peptide research literature mapped onto golf, Hyrox, CrossFit, cycling and the strength sports.
A research-first overview of TB-500 - how it relates to Thymosin Beta-4, what the preclinical literature actually studies, the human-trial gap, and why it is prohibited in tested sport.
The A2 pulley rupture is the climber's ACL. Why BPC-157 is the most-discussed peptide in climbing forums, and the IFSC anti-doping reality.
30,000 ground impacts, eccentric quad damage, mitochondrial debt. The peptide-recovery research literature mapped onto the 26.2-mile recovery curve.
The peptide-research overlap with combat-sports recovery, and the USADA / VADA / WADA framing every fighter needs.
The peptide-research overlap with powerlifting recovery - tendon, lumbar, CNS - and the IPF / USPA testing reality.
A research look at why BPC-157 keeps appearing in tattoo recovery conversations - skin barrier repair, vascularisation, collagen remodelling.
High-intensity volume meets the peptide soft-tissue literature. A research-framed map.
IT band, lumbar disc, mitochondrial efficiency - the peptide endurance-recovery literature, plain.
Eight runs, eight stations, one body. The peptide recovery research mapped onto the Hyrox gauntlet.
The GH axis, recovery, fat-loss and connective-tissue compounds - what the literature shows, and what's WADA-prohibited.
Five structures take the load of every swing. The TB-500 soft-tissue research literature, plain - and where it sits in the recovery conversation.
$30,000-a-year longevity clinics. The exact compounds Silicon Valley and A-list actors have been running for over a decade.
GHK-Cu, Melanotan and the dermatology research literature: collagen density, copper peptide mechanism, hair follicle research.
What the published research literature says about GHK-Cu dosage - topical %, subcutaneous μg ranges, frequency, reconstitution, safety and onset.
Sweden has one of the highest melanoma incidence rates in Europe. The Nordic epidemiology, the published primary-prevention evidence, and where Melanotan-2 sits in the melanocortin research landscape - including the case reports that complicate the 'tanning shortcut' narrative.
A tattoo artist had to switch to a deeper needle mid-session and noted the skin felt thicker - without knowing GHK-Cu was being studied. The dermal-density literature, plain.
Signal peptides, copper peptides and collagen peptides - what the dermatology literature actually supports, in plain English.
Copper peptides and hair-follicle science - what is studied, what is not established, and why research framing matters.
With search interest up over 1,000% YoY, GHK-Cu is one of the most studied regenerative peptides. Here's what the research shows.
Reconstitution, storage, and COA reading - everything you need to handle research-grade vials correctly.
Enter vial mg, water mL, and desired dose - instantly see units to draw. Presets for BPC-157, GLP-1 RC-S, TB-500 and more.
The label tells you the claim; the COA shows whether it has been tested. Mass spectrometry for identity, HPLC for purity, batch numbers for traceability - and the red flags that signal marketing over evidence.
The standard solvent for research-peptide reconstitution — what it is, bacteriostatic vs sterile water, how much to add, shelf life, storage and the mixing math.
The per-batch CoA, third-party HPLC/mass-spec, reference standards and grey-market red flags - a research-literate checklist for vetting a peptide supplier.
Vetting suppliers, the Certificate of Analysis, HPLC purity and the research-use-only framing - a research-literate sourcing guide.
Understanding HPLC purity, mass spectrometry, endotoxin levels, and every section of a peptide COA.
Optimal storage for lyophilised and reconstituted peptides. Temperature, light, moisture control, and shelf life by peptide type.
Learn how to properly reconstitute lyophilised peptides with bacteriostatic water. Complete guide with dosage calculator.
What peptides actually are, how they signal, the elite-protocol context, and the most-researched compounds in 2026.
Reconstitute, calculate dosage, and store peptides. Free interactive calculator + step-by-step guides.
A research-first breakdown of BPC-157 - the body protection compound, the preclinical evidence base, the human-trial gap, and why the honest answer separates interest from proof.
A GHRH analogue with a genuine but narrow approved use. What the visceral-fat research shows, how tesamorelin differs from recovery peptides, and why general fat-loss and longevity claims overreach.
A 2026 Frontiers in Aging review maps nine therapeutic peptides onto the hallmarks of aging. What the authors found - and the gaps they flag.
How PT-141 works, nasal spray administration, clinical evidence, and how it compares to traditional sexual dysfunction treatments.
Both hit the ghrelin receptor — but hexarelin pushes harder (and reaches the heart via CD36) while ipamorelin stays clean and selective. A research comparison.
Des(1-3) vs Long R3 IGF-1 - structure, half-life, binding-protein affinity, the recombinant-protein research context, and the anti-doping reality. Research use only.
Two different receptors, one shared goal — releasing growth hormone. How the selective ghrelin agonist ipamorelin and the GHRH analogue sermorelin differ, and why they're studied together.
Signalling peptides, peptide hydrogels and scaffolds, and growth factors - how the peptide literature intersects with stem-cell and regenerative-medicine research.
Both prompt the pituitary through the GHRH receptor — but tesamorelin is the stabilised, more potent molecule studied for visceral fat, while sermorelin is the classic GHRH 1-29 fragment. A research comparison.
A neutral research-side guide to BPC-157 - mechanism, pre-clinical evidence, the human-trial gap, the Wolverine stack with TB-500, and the research-compound posture.
A research-side guide to CJC-1295 (modified GHRH 1-29) and ipamorelin (selective ghrelin-receptor pentapeptide) - mechanisms, DAC vs no-DAC, synergy and the research-compound posture.
A research-side guide to tesamorelin - mechanism, NIH visceral-adipose-tissue data, comparison with CJC-1295 and sermorelin, and the research-compound posture.
Amino acids are the monomers; peptides are short chains of them joined by peptide bonds. The plain-English structural relationship, research framed.
A neutral map of which research peptides are drawing attention in 2026 - trend commentary attributed, no human-use claims.
Two different questions - topical skincare layering vs research-reagent handling. Why combination protocols are human-use guidance we do not provide.
How peptide quality is actually verified - HPLC/LC-MS, the Certificate of Analysis, lyophilised handling, storage, supplier selection, and global shipping. Research use only.
The sourced version of every 'what peptide does [celebrity] use' search - BPC-157, NAD+, the Wolverine stack - attributed to ELLE, TIME, The Times, Yahoo and AOL.
A neutral explainer on how clinics and the literature frame testosterone replacement therapy versus peptide approaches. Research context only.
A neutral explainer on how the term 'peptide therapy' is used - approved peptide medicines vs investigational compounds, and why the language is regulated.
MOTS-c is a mitochondrial-derived peptide at the intersection of metabolic regulation and longevity research.
Every major peptide benefit traced back to peer-reviewed studies, with the mechanisms that make each one work.
Short chains of amino acids that tell the body to heal, repair and regenerate. Inside the science the top 1% have quietly relied on for over a decade.
FDA approval status, US / UK / EU legality, safety frameworks, clinician perspectives, and the industry analysis pieces.
On July 23, 2026, the FDA's compounding advisory committee discusses BPC-157 and TB-500 bulk substances. What it means for regenerative peptide research - and why a review is not an approval.
From Category 2 prohibition (2023) to a fresh 503A review (2026): the notice, the 12 peptides, the lawsuits, the policy push, and what the July 2026 PCAC meeting decides.
The FDA's Pharmacy Compounding Advisory Committee reviews BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Semax and Epitalon on July 23-24, 2026. A review is not an approval - here is what it actually means.
Not exactly. BPC-157 is a research-use-only compound the FDA's 2023 compounding review kept off the 503A Bulks List for human use - and it returns for discussion in July 2026.
No - BPC-157 is a research compound, not an FDA-approved drug. The 2026 status explained, including the July 2026 503A compounding review.
No - Epitalon (Epithalon) is a research compound, not an FDA-approved drug. The 2026 status and the July 2026 review, explained.
A compounding-list review is not a change of FDA position. What the July 23-24, 2026 advisory committee meeting really means for BPC-157, TB-500, Semax and Epitalon.
No - Semax is a research compound in the US, not an FDA-approved drug (though it is a registered medicine in Russia). The 2026 status and July 2026 review, explained.
No - TB-500 is a research compound related to thymosin beta-4, not an FDA-approved drug. The 2026 status, the July 2026 review and the WADA sport ban, explained.
KPV - the anti-inflammatory tripeptide derived from alpha-MSH - is on the FDA's July 2026 compounding agenda. What it is, the research context, and why a review is not an approval.
As peptides become a bigger public-health story, audiences need clearer information about BPC-157, TB-500, Semax, Epitalon and the FDA's 2026 review. FDA review is not approval.
On July 24, 2026, the FDA's compounding advisory committee discusses Semax, Epitalon and Emideltide (DSIP). What it could mean for neuro-longevity peptide research - and why a review is not an approval.
As the FDA prepares to review peptide-related bulk substances in July 2026, peptides are moving toward mainstream health news. Why it matters - and how to read the coverage responsibly.
FDA-approved injectables vs unapproved research compounds, what the 2026 press wave reported, and the safety questions doctors raise - a research-literate explainer.
GMP and pharmacopoeia standards vs research-use-only purity, why 'pharma grade' is often marketing, and how to read what's really in the vial.
Crypto rails, AI discoverability and per-batch supply-chain transparency are reshaping the research compound space. The full-stack 2026 explainer.
The honest answer to the grassroots recovery question: research compounds are not a recovery option for amateur athletes. The RUO framing, explained.
Why Europe is setting the global pace in both iGaming and peptide biotech - the regulatory maturity, consumer psychology and brands defining 2026.
Peptides are legal to buy and possess for research in the UK, but the MHRA bars marketing them for human use unless licensed as medicines. The research-use line, explained.
What the FDA's compounding decision actually said, the safety concerns behind it, and why it underlines that research material is not for human use.
Physicians, via the AMA, on limited FDA review, animal-only evidence and open dosing questions - and why that is what 'research use only' means.
How research peptides are regulated by jurisdiction - medicinal-product status, the EMA framework, and what 'research use only' actually means.
How peptide safety is actually assessed - purity, contamination, the Certificate of Analysis, and what 'research use only' means.
Peptides and steroids are different chemical and mechanistic classes - here is the plain-English difference.
7 peptides are FDA-approved. 40+ are in active clinical trials. A complete map of the regulatory pipeline.
Guides & tools